Get the Stockscreener App
14.56
3.97%
-0.41
Replimune Group Inc stock is traded at $14.56, with a volume of 2.47M.
It is down -3.97% in the last 24 hours and up +40.52% over the past month.
Replimune Group Inc is a clinical-stage biotechnology company committed to applying its expertise in the field of oncolytic immunotherapy to transform the lives of cancer patients through novel oncolytic immunotherapies. Its proprietary oncolytic immunotherapy product candidates are designed and intended to maximally activate the immune system against cancer. Oncolytic immunotherapy is an emerging drug class. The proprietary RPx platform is based on a novel, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added that are intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. It operates in single segment of developing oncolytic immunotherapies for the treatment of cancer.
See More
Previous Close:
$14.97
Open:
$14.65
24h Volume:
2.47M
Relative Volume:
0.40
Market Cap:
$1.37B
Revenue:
-
Net Income/Loss:
$-313.94M
P/E Ratio:
-4.1529
EPS:
-3.506
Net Cash Flow:
$-284.57M
1W Performance:
+5.16%
1M Performance:
+40.52%
6M Performance:
+98.00%
1Y Performance:
+158.54%
1-Day Range:
$14.05
$14.69
1-Week Range:
$13.20
$15.71
52-Week Range:
$1.50
$15.71
Replimune Group Inc Stock (REPL) Company Profile
Name
Replimune Group Inc
Sector
Industry
Phone
(781) 222-9600
Address
500 UNICORN PARK, WOBURN, MA
Compare REPL vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
REPL
Replimune Group Inc
|
14.57 | 1.40B | 0 | -313.94M | -284.57M | -3.506 |
VRTX
Vertex Pharmaceuticals Inc
|
515.89 | 128.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
806.79 | 82.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
992.63 | 53.26B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
215.22 | 43.66B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
362.16 | 39.31B | 5.76B | 514.49M | 1.10B | 4.4813 |
Replimune Group Inc Stock (REPL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-13-26 | Downgrade | BMO Capital Markets | Market Perform → Underperform |
| Apr-13-26 | Downgrade | H.C. Wainwright | Buy → Sell |
| Apr-13-26 | Downgrade | JP Morgan | Neutral → Underweight |
| Apr-13-26 | Downgrade | Jefferies | Buy → Hold |
| Apr-13-26 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Apr-13-26 | Downgrade | Wedbush | Outperform → Neutral |
| Apr-10-26 | Downgrade | Piper Sandler | Overweight → Neutral |
| Nov-03-25 | Upgrade | BMO Capital Markets | Underperform → Market Perform |
| Oct-27-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-20-25 | Upgrade | JP Morgan | Underweight → Neutral |
| Oct-20-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-20-25 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-20-25 | Upgrade | Wedbush | Neutral → Outperform |
| Sep-19-25 | Downgrade | JP Morgan | Neutral → Underweight |
| Jul-30-25 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Jul-23-25 | Downgrade | BMO Capital Markets | Outperform → Underperform |
| Jul-23-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Jul-23-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jul-22-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-22-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jul-22-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-22-25 | Downgrade | Wedbush | Outperform → Neutral |
| Jun-20-25 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-28-24 | Initiated | ROTH MKM | Buy |
| Apr-17-23 | Resumed | Piper Sandler | Overweight |
| Nov-19-21 | Initiated | Piper Sandler | Overweight |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Nov-17-20 | Initiated | BTIG Research | Buy |
| Nov-02-20 | Initiated | Jefferies | Buy |
| Oct-15-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jul-01-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-05-20 | Initiated | Barclays | Overweight |
| Sep-04-19 | Initiated | ROTH Capital | Buy |
| Jul-23-19 | Initiated | Chardan Capital Markets | Buy |
| Jul-12-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-08-19 | Initiated | H.C. Wainwright | Buy |
| Apr-25-19 | Initiated | Wedbush | Outperform |
| Jan-23-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-14-18 | Initiated | JP Morgan | Overweight |
| Aug-14-18 | Initiated | Leerink Partners | Outperform |
View All
Replimune Group Inc Stock (REPL) Latest News
Bronstein, Gewirtz & Grossman LLC Urges Replimune Group, - GlobeNewswire
REPL DEADLINE: Levi & Korsinsky Reminds Replimune Group, - GlobeNewswire
2026-08-16 | REPL INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Replimune Group, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! | NDAQ:REPL | Press Release - Stockhouse
Replimune Raises $150 Million To Fund TUDRIQEV Launch And Confirmatory Trial - Pulse 2.0
REPL SWOT Analysis: FDA Approval of TUDRIQEV Marks a Turning Point - GuruFocus
REPL Ignites On Doctor Fury Against FDA’s Melanoma Drug Snub — Health Sec Steps Back - Stocktwits
Replimune’s First Commercial Drug Arrives—With A 2027 Cash Cliff And 2030 Finish Line - Stocktwits
Replimune Group (NASDAQ:REPL) Releases Quarterly Earnings Results - marketbeat.com
REPL Stock On Track To Hit All-Time Lows – Here’s Why This Analyst Slashed Price Target By 85% - Stocktwits
REPL INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Replimune Group, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Form 8K Replimune Group Inc For: 7 August By Investing.com - Investing.com Nigeria
Replimune Group, Inc. Files For Mixed Shelf Size Not Disclosed - TradingView
Replimune (NASDAQ: REPL) secures FDA accelerated approval and raises $141M - Stock Titan
Replimune Group (REPL): Ridgeback Capital now reports 3.5% ownership stake - Stock Titan
Why Is Replimune (NASDAQ:REPL) Drawing Attention After Its Oncology Approval? - Kalkine Media
Replimune Group Releases Q1 2027 Financial Results - AlphaStreet
2026-08-14 | REPL INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Replimune Group, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! | NDAQ:REPL | Press Release - Stockhouse
Replimune Group stock may move 5.6% on earnings release By Investing.com - Investing.com Canada
DEADLINE ALERT for BZAI, BABA, ALAR, and REPL: The Law - GlobeNewswire
REPL Shareholder Alert: Replimune Group, Inc. Securities Class Action LawsuitInvestors Should Contact The Gross Law Firm - WBOC TV
Replimune Group stock may move 5.6% on earnings release - Investing.com
Deadline Alert: Replimune Group, Inc. (REPL) Shareholders - GlobeNewswire
Replimune Q1 EPS $(0.72) beats estimate; FDA approves TUDRIQEV - scanx.trade
Form 8K Replimune Group Inc For: 14 August By Investing.com - Investing.com Australia
Replimune Reports Fiscal First Quarter 2027 Financial Results And Provides Corporate Update - TradingView
Replimune Fiscal Q1 Net Loss Narrows - marketscreener.com
REPL: FDA approval of TUDRIQEV and new financing drive launch and extend cash runway for over a year - TradingView
Replimune Reports Fiscal First Quarter 2027 Financial Results and Provides Corporate Update - The Manila Times
Replimune Reports $69.8 Million First-Quarter Loss After TUDRIQEV FDA Approval - Quiver Quantitative
REPL Stock Lost 19% Of Its Value Today – Why Did The FDA Refuse Approval For Its Experimental Melanoma Drug? - Stocktwits
REPL SHAREHOLDER ALERT: Securities Fraud Lawsuit Filed on - GlobeNewswire
Replimune Group (REPL) Wins FDA Approval For Advanced Melanoma Treatment - Yahoo Finance
Bronstein, Gewirtz & Grossman, LLC Is Investigating Replimune Group Inc. (REPL) And Encourages Shareholders to Connect - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Replimune Gro - The National Law Review
SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of October 5, 2026 in Replimune Group, Inc. LawsuitREPL - Morningstar
Replimune Group Stock Short Interest Rises to 57.95% - Moomoo
Bronstein, Gewirtz & Grossman LLC Urges Replimune Group, Inc. Investors to Act: Class Action Filed Alleging Investor Harm - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming DeadlinesREPL - PR Newswire
Replimune Group (NASDAQ:REPL) Insider Sells 11,447 Shares of Stock - marketbeat.com
Replimune Group (NASDAQ:REPL) CAO Sells 7,632 Shares - marketbeat.com
Insider Selling: Replimune Group (NASDAQ:REPL) CEO Sells 39,341 Shares - marketbeat.com
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Replimune Group Inc. (REPL) And Encourages Shareholders to Reach Out - ACCESS Newswire
Replimune group CEO Sushil Patel sells $510,252 in stock By Investing.com - Investing.com Nigeria
Replimune CFO Emily Hill sells $148,480 in shares for tax withholding - Investing.com Nigeria
Replimune group CEO Sushil Patel sells $510,252 in stock - Investing.com
Replimune Group Chief Executive Officer Sold Shares Worth Over $510K - TradingView
What happened at FDA? Replimune approval raises questions - The Cancer Letter
REPL Class Action ReminderRobbins LLP Reminds Investors - GlobeNewswire
Levi & Korsinsky Reminds Replimune Group, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of October 5, 2026REPL - PR Newswire
Cantor Fitzgerald reiterates Replimune stock rating on launch potential By Investing.com - Investing.com Canada
Replimune Group Inc Stock (REPL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Replimune Group Inc Stock (REPL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Hill Emily Luisa | Chief Financial Officer |
Aug 10 '26 |
Sale |
12.97 |
11,448 |
148,481 |
225,108 |
| Xynos Konstantinos | Chief Medical Officer |
Aug 10 '26 |
Sale |
12.97 |
11,447 |
148,468 |
224,215 |
| Schwendenman Andrew | Chief Accounting Officer |
Aug 10 '26 |
Sale |
12.97 |
7,632 |
98,987 |
99,425 |
| Sarchi Christopher | Chief Commercial Officer |
Jun 01 '26 |
Sale |
9.24 |
12,000 |
110,880 |
180,962 |
| Xynos Konstantinos | Chief Medical Officer |
May 18 '26 |
Sale |
5.08 |
14,023 |
71,237 |
235,662 |
| Schwendenman Andrew | Chief Accounting Officer |
May 18 '26 |
Sale |
5.08 |
7,894 |
40,102 |
107,057 |
| Sarchi Christopher | Chief Commercial Officer |
May 18 '26 |
Sale |
5.08 |
8,626 |
43,820 |
192,962 |
| Astley-Sparke Philip | Director |
May 18 '26 |
Sale |
5.08 |
17,657 |
89,698 |
1,412,414 |
| Patel Sushil | Chief Executive Officer |
May 18 '26 |
Sale |
5.08 |
37,324 |
189,606 |
747,492 |
| Hill Emily Luisa | Chief Financial Officer |
May 18 '26 |
Sale |
5.08 |
7,812 |
39,685 |
236,556 |
2.24%
1.78%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):